-
Uncategorized4 weeks ago
A ‘renaissance for biomedicine’: human brain organoids model development for 5 years
Scientists’ ability to recapitulate the human brain in a dish has always been hindered by the inability to model the full capacity of the brain and...
-
Uncategorized4 weeks ago
Sandoz inks $322M Henlius deal for rights to as many as 10 biosimilars
The initial batch of biosimilars includes copies of Amgen, Eli Lilly and GSK drugs that collectively generate billions of dollars in annual revenues.
-
Uncategorized4 weeks agoSTAT+: Pharmalittle: We’re reading about a setback for Eyepoint, a win for Amylyx, and more
Top of the morning to you. Gray skies are hovering over the Pharmalot campus right now, but our spirits remain sunny, nonetheless. Why? We will trot...
-
Uncategorized4 weeks ago
LEO adds to dermatology portfolio with $435M deal for late-stage rare disease drug
This is the third recent acquisition conducted by Denmark’s LEO Pharma in medical dermatology, a portfolio that marked 12% growth in the first half of the...
-
Uncategorized4 weeks ago
Rebounding biotech funds expected to spur CDMO growth within year
With demand for pharma services historically lagging changes in biotech funding, analysts expect CDMOs to experience an uptick in activity in late 2026 or early 2027.
-
Uncategorized4 weeks ago
Regeneron ends eye disease study due to antibody’s safety profile
The discontinuation of the uveitis study adds to Regeneron’s series of clinical setbacks, including the Phase 3 failures of the Dupixent follow-up itepekimab and an investigational...
-
Uncategorized4 weeks ago
Amylyx’s bet on a GLP-1 blocker pays off
A late-stage trial found the drug, which Amylyx bought for cheap in a bankruptcy auction, was effective at regulating blood sugar in patients who’d just undergone...
-
Uncategorized4 weeks ago
Amylyx eyes FDA filing for GLP-1 blocker after late-stage win in post-bariatric hypoglycemia
With a Phase 3 trial reducing serious and severe hypoglycemic episodes following weight loss surgery, Amylyx Pharmaceuticals plans to file for approval this year. If granted...
-
Uncategorized4 weeks agoSTAT+: A pill that mimics exercise? Early results on drug designed to maintain both weight loss and muscle mass
If you could design an oral treatment that limits appetite and mimics some effects of physical activity, you might call it exercise in a pill. Now...
-
Uncategorized4 weeks ago
Assessing shared failures with AI is key to cell and gene therapy’s evolution
If we guard our secrets, patients suffer. Only through a commitment to transparency and data sharing—and artificial intelligence—can we make cell and gene therapies safer and...
FDA clears first generic radioligand drug; Sionna turns to layoffs
WCLC ‘26: A new ‘ADC era,’ China questions and AstraZeneca’s spotlight
Ensuring safety and accountability in China’s biomedical translation system
Scientists turn pig semen extract into eye drops that kill cancer in mice
Novartis to pay $2B upfront to take next-gen PI3Kα inhibitor from Synnovation
